Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Operating Leases (2020 - 2025)

Historic Operating Leases for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $31.7 million.

  • Tango Therapeutics' Operating Leases fell 892.33% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.7 million, marking a year-over-year decrease of 892.33%. This contributed to the annual value of $34.0 million for FY2024, which is 759.81% down from last year.
  • As of Q3 2025, Tango Therapeutics' Operating Leases stood at $31.7 million, which was down 892.33% from $32.5 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Operating Leases high stood at $39.9 million for Q3 2022, and its period low was $6.1 million during Q3 2021.
  • For the 5-year period, Tango Therapeutics' Operating Leases averaged around $33.9 million, with its median value being $35.8 million (2024).
  • In the last 5 years, Tango Therapeutics' Operating Leases surged by 55605.19% in 2022 and then crashed by 892.33% in 2025.
  • Over the past 5 years, Tango Therapeutics' Operating Leases (Quarter) stood at $6.1 million in 2021, then surged by 546.43% to $39.4 million in 2022, then dropped by 6.41% to $36.8 million in 2023, then fell by 7.6% to $34.0 million in 2024, then decreased by 6.99% to $31.7 million in 2025.
  • Its Operating Leases stands at $31.7 million for Q3 2025, versus $32.5 million for Q2 2025 and $34.1 million for Q1 2025.